Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives

Gut Microbes. 2022 Jan-Dec;14(1):2120747. doi: 10.1080/19490976.2022.2120747.

Abstract

Helicobacter pylori (H. pylori) is the main cause of gastric adenocarcinoma. However, the traditional antibiotic treatment of H. pylori is limited due to increased antibiotic resistance and low efficacy; low drug delivery efficiency and difficulties in eradicating H. pylori that is present intracellularly or in biofilms cause further setbacks. Biomaterials that can protect drugs against stomach acid, target lesions, control drug release, destroy biofilms, and exhibit unique antibacterial mechanisms and excellent biocompatibility have emerged as attractive tools for H. pylori eradication, particularly for drug-resistant strains. Herein, we review the virulence mechanisms, current drug treatments, and antibiotic resistance of H. pylori strains. Furthermore, recent advances in the development of biomaterials, including nanoparticles (such as lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles), microspheres, and hydrogels, for effective and precise therapy of H. pylori and different types of therapeutic mechanisms, as well as future perspectives, have also been summarized.

Keywords: Helicobacter pylori; biomaterials; hydrogels; microspheres; nanoparticles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Biocompatible Materials / pharmacology
  • Drug Resistance, Microbial
  • Gastrointestinal Microbiome*
  • Helicobacter pylori*

Substances

  • Anti-Bacterial Agents
  • Biocompatible Materials

Grants and funding

This work was supported by the National Natural Science Foundation of China (Grant nos. 82072051 and 81771964), the Strategic Consulting Research Project of Chinese Academy of Engineering (2021-ZX-12) and Project of Shanghai Municipal Health Commission (2019SY001).